Stockscreener 앱 받기
6.21
0.16%
0.010
시장 영업 전:
6.13
-0.08
-1.29%
Decoy Therapeutics Inc 주식(DCOY)의 최신 뉴스
DCOY Price Today: Decoy Therapeutics Inc. Stock Price, Quote & Chart - MEXC
Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline - BioSpace
Transcript : Decoy Therapeutics Inc.Special Call - marketscreener.com
Decoy Therapeutics outlines antiviral pipeline milestones By Investing.com - Investing.com South Africa
Decoy Therapeutics outlines antiviral pipeline milestones - Investing.com
Decoy Therapeutics Launches Multi-Virus Antiviral Platform - Intellectia AI
12 Health Care Stocks Moving In Tuesday's After-Market Session - Sahm
DCOY Technical Analysis & Stock Price Forecast - Intellectia AI
Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026 - Finviz
Decoy Therapeutics Inc (STU:FP11) Stock Earnings Transcripts - GuruFocus
Decoy Therapeutics Inc (STU:FP11) Stock Price & 30 Year Financial Data - GuruFocus
Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Bitget
Decoy Therapeutics Inc. (DCOY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Decoy Therapeutics regains Nasdaq minimum bid price compliance By Investing.com - Investing.com Australia
Decoy Therapeutics regains Nasdaq minimum bid price compliance - Investing.com
Decoy Therapeutics Regains Nasdaq Compliance After Reverse Split - TipRanks
Decoy Therapeutics regains compliance with Nasdaq minimum bid price requirement - marketscreener.com
Decoy Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement - TradingView
Decoy Therapeutics regains Nasdaq minimum bid compliance after reverse split - TradingView — Track All Markets
Decoy Therapeutics (DCOY) restores Nasdaq bid-price compliance after reverse split - Stock Titan
DCOY: 2025 net loss rose to $12.5M, with cash runway into late 2026 but going concern risk persists - TradingView
Decoy Therapeutics 10-K: Net loss $12.52M, EPS $(129.10) - TradingView — Track All Markets
Decoy Therapeutics (NASDAQ: DCOY) details AI antiviral platform, merger and reverse stock splits - Stock Titan
Decoy Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Decoy Therapeutics Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Total liabilities & shareholders' equities of Decoy Therapeutics Inc. – FWB:FP11 - TradingView
Nabriva Therapeutics (NASDAQ:NBRV) and Decoy Therapeutics (NASDAQ:DCOY) Head to Head Survey - Defense World
If You Invested $1,000 in Salarius Pharmaceuticals Inc (SLRX) - Stock Titan
Decoy Therapeutics Inc.: Fundamental Analysis and Financial Ratings | | US79400X6022 - marketscreener.com
Decoy Therapeutics Inc.: Fundamental Analysis and Financial Ratings | FP11 | US79400X6022 - marketscreener.com
Decoy Therapeutics Inc.: Fundamental Analysis and Financial Ratings | DCOY | US79400X6022 - marketscreener.com
Decoy Therapeutics partners with Quantori on AI peptide platform By Investing.com - Investing.com Nigeria
Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform - Lelezard
Decoy Therapeutics Inc. Earnings and Revenue – GETTEX:FP11 - TradingView
Debt to equity ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
EBIT per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Price to cash flow ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Free cash flow per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Net margin % of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Revenue per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Operating margin % of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Net current asset value per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Enterprise value to EBITDA ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Non-controlling/minority interest of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Price to book ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Total operating expenses of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
CapEx per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Equity in earnings of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
EBIT of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Total debt per share of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Debt to assets ratio of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Total common shares outstanding of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Operating income of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Enterprise value of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
EBITDA margin % of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Discontinued operations of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
2.69%
0.25%
자본화:
|
볼륨(24시간):